Amphotec liposomal amphotericin B data

SEQU and university collaborators reported positive results of a Phase I dose escalation trial in 75 bone marrow transplant patients with invasive fungal infections. As reported in The Journal of Infectious Diseases, Amphotec was safe at doses up to 7.5 mg/kg/day with antifungal activity, no appreciable renal toxicity and manageable infusion-related side effects. No infusion-related toxicities were seen in 32 percent of patients.

Patients with candida (55 percent), aspergillus (37 percent) and other fungal infections were enrolled in escalating dose groups ranging from 0.5 to 8 mg/kg. Doses were administered for up to six weeks. The underlying diagnosis was leukemia in 60 percent of patients. ...